XIAPEX (Collagenase Clostridium Histolyticum) Receives Positive CHMP Opinion
Collagenase Clostridium Histolyticum Recommended for Approval in the European Union (EU) for the Treatment of Dupuytren's Contracture in Adult Patients with a Palpable Cord
22-Dec-2010
- USA
The CHMP's positive recommendation will be reviewed by the European Commission, which has authority to approve medicines for the European Union. Pfizer anticipates a final decision from the European Commission by the end of the first quarter of 2011. The positive CHMP opinion is based on results from two pivotal studies, Collagenase Option for Reduction of Dupuytren's (CORD I and CORD II).
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
The sweet mysteries of the nervous system
Go to page
NicOx Completes Expansion of R&D Organization
Go to page
Biovitrum has Completed an Exploratory Clinical Phase II Study in Glaucoma
Go to page
Causus_maculatus
Go to page
Hennig Arzneimittel GmbH & Co. KG - Flörsheim, Germany
Go to page
Brain development: Fate of brain progenitor cells hinges on getting the timing right
Go to page
Othera announces positive Interim Phase 2 Results of OT-551 Eye Drop Treatment for Dry AMD
Go to page
Mediso - Budapest, Hungaria
Go to page
Malaria's key survival protein identified, offering drug hope
Go to page
Saliva
Go to page
CCS Chemie Consult Seidel - Böblingen, Germany
Go to page